Alentis Therapeutics

📍 Allschwil, Switzerland🗓 Founded 2019👥 32 employees💰 Last funded Oct 2021
Pharmaceutical Manufacturing🌐 alentis.ch
Website LinkedIn
Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis.  Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1.  Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver.  The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).  Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch
6
Total investors
6
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography5 countries
Switzerland
2
France
1
Hong Kong SAR
1
Germany
1
United States
1
Investor activity2019–2021 · investors recorded per year
201932020120212
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Alentis Therapeutics?
Alentis Therapeutics has 6 investors on record on gritt.io, including 6 early-stage backers.
When did Alentis Therapeutics last raise funding?
The most recent investment in Alentis Therapeutics recorded on gritt.io was in October 2021.
When was Alentis Therapeutics founded?
Alentis Therapeutics was founded in 2019.
What industry is Alentis Therapeutics in?
Alentis Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Alentis Therapeutics based?
Alentis Therapeutics is headquartered in Allschwil, Switzerland.